Hospira Inc
- All
- News
- Videos
-
Pfizer Revenue Rises 11% In Second Quarter
Pfizer Inc's quarterly revenue rose about 11 per cent, driven by sales of newer drugs and the acquisition of hospital products company Hospira last year.
-
Pfizer Surges 6% as Parent Plans to Buy Hospira
Pfizer Inc on Thursday said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectable drugs and copies of biotech medicines.
-
Pfizer to Buy Hospira for $15 Billion
Pfizer Inc said it would buy Hospira Inc for about $15 billion (Rs 91,500 crore at 1 dollar = 61 rupees) to boost its portfolio of generic injectable drugs and copies of biotech medicines.
-
Wockhardt, Cadila, Hospira Recall Drugs in US
Drug firms Wockhardt, Cadila Healthcare and Hospira are voluntarily recalling certain lots of drugs in the US, according to the US Food and Drug Administration (FDA).
-
US regulator raises concerns at Tamil Nadu Hospira facility
The FDA said it found that surfaces in the facility were not always sanitised prior to use and that sterile drug products were not protected from contamination.
-
Pfizer Revenue Rises 11% In Second Quarter
Pfizer Inc's quarterly revenue rose about 11 per cent, driven by sales of newer drugs and the acquisition of hospital products company Hospira last year.
-
Pfizer Surges 6% as Parent Plans to Buy Hospira
Pfizer Inc on Thursday said it would buy Hospira Inc for about $15 billion to boost its portfolio of generic injectable drugs and copies of biotech medicines.
-
Pfizer to Buy Hospira for $15 Billion
Pfizer Inc said it would buy Hospira Inc for about $15 billion (Rs 91,500 crore at 1 dollar = 61 rupees) to boost its portfolio of generic injectable drugs and copies of biotech medicines.
-
Wockhardt, Cadila, Hospira Recall Drugs in US
Drug firms Wockhardt, Cadila Healthcare and Hospira are voluntarily recalling certain lots of drugs in the US, according to the US Food and Drug Administration (FDA).
-
US regulator raises concerns at Tamil Nadu Hospira facility
The FDA said it found that surfaces in the facility were not always sanitised prior to use and that sterile drug products were not protected from contamination.
